Skip to main content
Fig. 11 | Journal of Ovarian Research

Fig. 11

From: Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer

Fig. 11

Brms1 TMRE Cell Line Comparison. p53-Bad* constructs under control of Brms1 show significantly more apoptosis in all ovarian cancer cell lines than those under control of CMV compared to normal BJ cells. For each column n = 3, and the data were analyzed using 2-way ANOVA and Bonferroni’s post-test. Each * corresponds to a P value < 0.001, and each “n” to a non-significant P value when the respective ovarian cancer cell column is compared to the normal cell (BJ) column in the same category with Bonferroni’s post-test

Back to article page